Trending News

Non-Hodgkins lymphoma
#CAR-T #Cell therapy #Lymphoma #Natural killer cells #Phase I trial

CAR-NK therapy treats incurable lymphoma in Phase I trial

In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL).  QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More

#Cancer Research #News #Trending News

#European Union #GlobalData #Pharmaceutical industry #Politics #United States

Experts weigh the impact of Trump’s proposed tariff on pharma

The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200-250% tariff on drug imports, which could significantly increase prices and reduce profit margins.   While the tariffs are set to be announced soon, a grace period of 12 to 18 months has been indicated before they… Read More

#Business & Investment #News #Trending News

Gene sequence
#Chronic Fatigue Syndrome #Genetics / genomics #University of Edinburgh

Study finds key genetic differences in people with ME/CFS

Scientists have discovered that people diagnosed with ME/CFS have significant differences in their DNA, offering the first robust evidence that genes contribute to a person’s chance of developing the disease.  Initial findings have uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome)… Read More

#News #Trending News

Vaccine production
#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #United States

US cancels mRNA vaccine development contracts

The US Department of Health and Human Services (HHS) has announced the beginning of a “coordinated wind-down” of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA).   The department says the decision follows a comprehensive review of mRNA-related investments initiated during the… Read More

#News #Trending News

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

#Big pharma #Europe #Pharmaceutical industry #Switzerland #United States

Trump increases pressure on pharma and imposes new tariffs

US President Donald Trump has sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash US prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed an executive order in May demanding drugmakers cut US medicine prices to match… Read More

#Business & Investment #News #Trending News

Older adult receiving vaccine
#Dementia #GSK #Immunology / Virology & Vaccines #Neuroscience #Shingles

RWD shows shingles vaccine reduces dementia risk

GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.  Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More

#News #Trending News

Neurons
#Amyotrophic lateral sclerosis (ALS) #Biogen #MHRA #MND #Neuroscience

First new ALS treatment approved in UK in 30 years

Biogen’s Qalsody (tofersen) has been approved in the UK as the first therapy to treat a rare, genetic form of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND).  The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for tofersen through the International Recognition Procedure (IRP)… Read More

#News #Regulatory #Trending News

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

Biogen facility in Cambridge, US
#Biogen #Investment #Manufacturing #United States

Biogen commits $2b to modernise US manufacturing facility

Biogen has announced that it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). The announcement comes at the same time as AstraZeneca also revealed plans to invest in its US facilities. Since breaking ground in 1995, Biogen’s manufacturing in… Read More

#Business & Investment #News #Trending News

FDA
#AAV #FDA #Gene therapy #Manufacturing #Rare disease #Ultragenyx

FDA raises manufacturing concerns for Ultragenyx gene therapy

The US Food and Drug Administration (FDA) has decided not to recommend Ultragenyx Pharmaceutical’s UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).   In its complete response letter (CRL), the FDA requested that the company provide additional information and improvements related to… Read More

#News #Regulatory #Trending News

#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #United States

Medical societies sue RF Kennedy Jr for “unlawful” vaccine changes

A group of medical professional societies have filed a lawsuit against Robert F Kennedy Jr in the US District Court for the District of Massachusetts to defend vaccine policy, and to put an end to what they call the Secretary’s “assault on science, public health and evidence-based medicine”. … Read More

#News #Trending News

Downing Street, London, UK
#Life sciences #Pharmaceutical industry #Politics #UK government

Pharma and UK government continue to debate drug prices

A “battle” between the UK government and the pharmaceutical industry over drug prices has forced the government to delay publication of its plan for the life sciences, according to The Financial Times.  The release of the life sciences review, initially scheduled for the start of this week, was delayed in… Read More

#Business & Investment #News #Trending News

Lungs
#Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Lung cancer #Oncology

First TROP2-directed therapy approved in the US for lung cancer

Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).  It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy.  The indication was approved under accelerated approval based… Read More

#News #Regulatory #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neuroscience

NICE rejects Alzheimer’s drugs for lack of cost-effectiveness

The UK National Institute for Health and Care Excellence (NICE) has reached its final decision on two Alzheimer’s treatments, denying their use on the NHS due to the therapies not providing “good value for money.”  Eli Lilly’s donanemab and Eisai’s lecanemab were under final draft guidance by NICE, which had… Read More

#News #Regulatory #Trending News

FDA headquarters
#Fast Track designation #FDA #Regulatory #United States

FDA priority programme reduces drug reviews to two months

The US Food and Drug Administration (FDA) has revealed plans to issue new Commissioner’s National Priority Vouchers (CNPVs) to companies “supporting US national interests”.  The new voucher may be redeemed by drug developers to participate in a novel priority programme that shortens drug review time from approximately 10-12 months to… Read More

#News #Regulatory #Trending News